Research Progress of Mrna Therapy: From Concept to Clinic
DOI:
https://doi.org/10.54097/qbqpn744Keywords:
mRNA, mRNA Vaccine, Clinical Trial, Lipid Nanoparticle.Abstract
mRNA therapeutics have emerged as a highly promising approach with the potential to revolutionize disease treatment. This review is to provide a comprehensive exploration of the fundamental principles and practical applications of mRNA therapy, from its conceptualization to clinical experimentation. Through a thorough examination of literature and analysis of clinical trial data, this review highlights the pharmaceutical potential of mRNA, including its adaptable design and efficient production. The advancements made in addressing challenges such as mRNA degradation and immunogenicity through modifications, purification techniques, and delivery systems are also discussed. Furthermore, it provides an overview of the progress in clinical trials of mRNA therapeutics, showcasing the promising developments in this field. Overall, this review emphasizes the significant contributions and implications of mRNA therapeutics in disease treatment, underscoring its potential to revolutionize the field and hold great promise for the future.
Downloads
References
Kelly E, Greenland M, Whalley P D D, et al.Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A Randomised Controlled Trial[J].The Journal of Infection, 2023.
Pardi,Norbert,Hogan,et al.mRNA vaccines - a new era in vaccinology[J].[2024-04-12].
Ferrucci P F, Pala L, Conforti F, et al.Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma[J].Cancers, 2021, 13(6):1383.
Shemesh CS, Hsu JC, Hosseini I, et al. Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities[J]. Mol Ther. 2021;29(2):555-570.
Crick F H C. On protein synthesis. [J]. Symp Soc Exp Biol, 1958, 12:138-163.
Pardee AB. NUCLEIC ACID PRECURSORS AND PROTEIN SYNTHESIS[J]. Proc Natl Acad Sci U S A. 1954;40(5):263-270.
Monod J, Pappenheimerjr A, Cohenbazire G. La cinétique de la biosynthèse de la β-galactosidase chez E. coli considérée comme fonction de la croissance[J]. BBA - Biochimica et Biophysica Acta, 1952, 9:648-660.
Pardee A B, Jacob F, Monod J. The genetic control and cytoplasmic expression of "Inducibility" in the synthesis of β-galactosidase by E. coli[J]. Journal of Molecular Biology, 1959, 1(2):165-178.
Matthaei H, Nirenberg M W. The dependence of cell-free protein synthesis in E. coli upon RNA prepared from ribosomes[J]. Biochemical & Biophysical Research Communications, 1961, 4(6):404-408.
Salter M W, Gingrich J R. METHOD FOR AMELIORATING PAIN BY MODIFICATION OF NMDA RECEPTORS THROUGH INHIBITION OF SRC[J]. [2024-04-13].
Wolff J A. Direct gene transfer into mouse muscle in vivo[J]. Science, 1990, 247(4949):1465-1468.
Dolgin E. The tangled history of mRNA vaccines[J]. Nature. 2021;597(7876):318-324.
Wang Y S, Kumari M, Chen G H, et al.mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications[J].Journal of Biomedical Science, 2023, 30(1).
Reardon S. Step aside CRISPR, RNA editing is taking off[J]. Nature. 2020;578(7793):24-27.
Curreri A, Sankholkar D, Mitragotri S, Zhao Z. RNA therapeutics in the clinic[J]. Bioeng Transl Med. 2022;8(1): e10374.
Cheng F, Wang Y, Bai Y, Liang Z, Mao Q, Liu D, Wu X, Xu M. Research Advances on the Stability of mRNA Vaccines[J]. Viruses. 2023; 15(3):668.
Jose Mateus et al., Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells[J]. Science374, eabj9853(2021).
Fabre AL, Colotte M, Luis A, Tuffet S, Bonnet J. An efficient method for long-term room temperature storage of RNA[J]. Eur J Hum Genet. 2014;22(3):379-385.
Karikó K. Modified uridines are the key to a successful message[J]. Nat Rev Immunol. 2021;21(10):619.
Xu X, Wang X, Liao Y P, et al.Use of a Liver-Targeting Immune-Tolerogenic mRNA Lipid Nanoparticle Platform to Treat Peanut-Induced Anaphylaxis by Single- and Multiple-Epitope Nucleotide Sequence Delivery[J].[2024-04-12].
Bollu A, Peters A, Rentmeister A. Chemo-Enzymatic Modification of the 5’ Cap to Study mRNAs[J]. Accounts of Chemical Research, 2022(9):55.
Cao J, Novoa E M, Zhang Z, et al.High-throughput 5′ UTR engineering for enhanced protein production in non-viral gene therapies[J].Nature Communications[2024-04-13].
Solodushko V, Fouty B. Terminal hairpins improve protein expression in IRES-initiated mRNA in the absence of a cap and polyadenylated tail[J]. Gene therapy, 2023(7/8):30.
Grudzien-Nogalska E, Jemielity J, Kowalska J, Darzynkiewicz E, Rhoads RE. Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells. RNA[J]. 2007;13(10):1745-1755.
JEMIELITY, J. Novel "anti-reverse" cap analogs with superior translational properties[J]. RNA, 2003, 9(9):1108-1122.
Bornewasser L, Domnick C, Kathschorr S. Stronger together for in-cell translation: natural and unnatural base modified mRNA[J]. Chemical Science, 2022(2).
Leppek K, Byeon G W, Kladwang W, et al.Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics[J].Nature Communications, 2022, 13.
Zhang H, Zhang L, Lin A, et al.Algorithm for Optimized mRNA Design Improves Stability and Immunogenicity[J]. 2020.
Inagaki M, Abe N, Li Z, et al.Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures[J].Nature Communications, 2023, 14(1).
Butora G, Stanton M, Miracco E J. Hydrophobic mrna cap analogs:PCT/US2016/057385[P]. WO 2017066782.
Kulkarni J A, Witzigmann D, Thomson S B, et al.The current landscape of nucleic acid therapeutics (vol 16, pg 630, 2021)[J].Nature nanotechnology, 2021(7):16.
Kate,E,Broderick, et al.Electroporation-enhanced delivery of nucleic acid vaccines[J].Expert Review of Vaccines, 2014.
Shirahata Y, Ohkohchi N, Itagak H, et al.New technique for gene transfection using laser irradiation[J].
Mellott A J, Forrest M L, Detamore M S. Physical Non-Viral Gene Delivery Methods for Tissue Engineering[J]. Annals of Biomedical Engineering, 2013, 41(3):446-468.
Chong ZX, Yeap SK, Ho WY. Transfection types, methods and strategies: a technical review[J]. PeerJ. 2021;9: e11165. Published 2021 Apr 21.
Yu G C, Qi S L. A carrier-free mRNA delivery method[P].CN113413467A, 2021.
Li M Y, Wang C L,et al.Engineering Multifunctional DNA Hybrid Nanospheres through Coordination-Driven Self-Assembly.[J].Angewandte Chemie, 2018.
Mendes BB, Conniot J, Avital A, et al. Nanodelivery of nucleic acids. Nat Rev Methods Primers[J]. 2022; 2:24.
Ghosh S, Brown A M, Jenkins C, et al.Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges[J]. 2020.
Akinc A, Maier M A, Manoharan M, et al.The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs[J].Nature Nanotechnology, 2019, 14(12):1084-1087.
Scheideler I P R. Lipid nanocarriers for microRNA delivery[J]. Chemistry and Physics of Lipids, 2020, 226.
Mulligan M J, Lyke K E, Kitchin N, et al.Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults[J].Nature[2024-04-19].
Wang X. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine[J]. The New England journal of medicine, 2021(16):384.
Baden L R, Sahly H M E, Essink B J, et al.Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.[J].Massachusetts Medical Society, 2021(5).
Kremsner PG, Mann P, Kroidl A, et al. Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: A phase 1 randomized clinical trial[J]. Wien Klin Wochenschr. 2021;133(17-18):931-941.
Pfizer. Pfizer and BioNTech's COVID-19 mRNA vaccine granted conditional approval by the European Union [EB/OL]. Pfizer China Official Website. 2020-11-18. https://www.pfizer.com.cn/en/news/press-release/673.
Townsend J P, Hassler H B, Sah P, et al.The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2[J]. 2022
Chong CY, Kam KQ, Zhang J, et al. Immunogenicity and safety of Sinovac-CoronaVac booster vaccinations in 12-17- year-olds with clinically significant reactions from Pfizer-BNT162b2 vaccination[J]. Vaccine. Published online April 6, 2024.
Bahl K, Senn J J, Yuzhakov O, et al. Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses[J]. Molecular Therapy the Journal of the American Society of Gene Therapy, 2017: S1525001617301569.
Xia H, Y.-R. H, X.-Y. Z, et al.Mpox virus mRNA-lipid nanoparticle vaccine candidates evoke antibody responses and drive protection against the Vaccinia virus challenge in mice[J].Antiviral research. 2023:216.
Sahin U, Oehm P, Derhovanessian E, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma[J]. Nature. 2020;585(7823):107-112.
Papachristofilou A, Hipp M M , Klinkhardt U ,et al.Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer[J].Journal for ImmunoTherapy of Cancer, 2019, 7(1).
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
